OS Therapies’ (OSTX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of OS Therapies (NYSEAMERICAN:OSTX) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $20.00 target price on the stock.

OS Therapies Stock Performance

Shares of NYSEAMERICAN OSTX opened at $1.41 on Friday. The company has a market cap of $49.65 million, a price-to-earnings ratio of -1.72 and a beta of -3.80. OS Therapies has a 12 month low of $1.12 and a 12 month high of $2.57. The stock has a 50-day moving average price of $1.40 and a two-hundred day moving average price of $1.67.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Susquehanna International Group LLP acquired a new position in shares of OS Therapies in the 3rd quarter worth approximately $29,000. Jane Street Group LLC acquired a new stake in shares of OS Therapies during the fourth quarter worth $39,000. Ground Swell Capital LLC acquired a new stake in shares of OS Therapies during the third quarter worth $40,000. Mercer Global Advisors Inc. ADV bought a new position in OS Therapies during the third quarter worth $40,000. Finally, Bridgeway Capital Management LLC bought a new position in OS Therapies during the second quarter worth $47,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.